Upcoming lung trials
SABR-OS - This trial will investigate if Stereotactic Ablative Body Radiotherapy (SABR) is more effective than surgery for early stage Non-Small Cell Lung Cancer (NSCLC) in patients considered at high risk of surgical resection.
Primary sponsor: TROG
TROG 16.03 (CORE) - this study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression free survival for patients with extra-cranial oligiometastatic disease that has spread from their lung, breast and/or prostate cancer
Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG